List of Figures
Figure 1: Generic Growth Strategies, Global, Revenues of the Top 10 Drugs Due for Patent Expiry ($m), 2013–2020
Figure 2: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006–2011
Figure 3: Generic Growth Strategies, Global, Revenues of Leading Generic Companies ($bn), 2010–2011
Figure 4: Generic Growth Strategies, Generic Market Share in Selected Countries, 2010
Figure 5: Generic Growth Strategies, Drivers and Restraints, 2012
Figure 6: Generic Growth Strategies, Global, Revenues of Top 10 Drugs Due for Patent Expiry ($m), 2013–2020
Figure 7: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006–2011
Figure 8: Generic Growth Strategies, ANDA Approvals by Month, The US, 2011–2012
Figure 9: Generic Growth Strategies, Number of EMA Authorized Generics, Europe, 2007–2012
Figure 10: Generic Growth Strategies, Number of Biosimilars Authorized by the EMA, Europe, 2006–2012
Figure 11: Generic Growth Strategies, The US, Generic Drug Cost-Sharing (%), 2011–2020
Figure 12: Generic Growth Strategies, SWOT Analysis, Teva, 2012
Figure 13: Generic Growth Strategies, SWOT Analysis, Sandoz, 2012
Figure 14: Generic Growth Strategies, SWOT Analysis, Mylan, 2012
Figure 15: Generic Growth Strategies, SWOT Analysis, Watson, 2012
Figure 16: Generic Growth Strategies, SWOT Analysis, Actavis, 2012
Figure 17: Generic Growth Strategies, SWOT Analysis, Hospira, 2012
Figure 18: Generic Growth Strategies, SWOT Analysis, Sanofi, 2012
Figure 19: Generic Growth Strategies, SWOT Analysis, Daiichi Sankyo, 2012
Figure 20: Generic Growth Strategies, SWOT Analysis, Aspen, 2012
Figure 21: Generic Growth Strategies, SWOT Analysis, STADA Arzneimittel AG, 2012